Endocrinology
Partner With Us
Advertisement
Conexiant chevron_right Endocrinology chevron_right OnceWeekly Combo Injection Cuts Weight by 20
From the Journals Conference News FDA & Government News ADA's 85th Scientific Sessions

Once-Weekly Combo Injection Cuts Weight by 20% 

A large 68-week clinical trial found that a once-weekly combination injection of cagrilintide and semaglutide led to significant and sustained weight loss in adults with overweight or obesity, with over half achieving at least 20% weight reduction.

Conexiant
Full Article Summary Notecard
  1. CagriSema combines cagrilintide and semaglutide for weight loss.
  2. 68-week REDEFINE 1 trial included 3,417 participants.
  3. Mean weight loss of 20.4% in CagriSema group.
  4. 91.9% lost at least 5% of body weight.
  5. Significant metabolic improvements noted.
  6. Common side effects included gastrointestinal issues.
  7. A follow-up study is assessing CagriSema in type 2 diabetes.

Source: The New England Journal of Medicine

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.